FT819 in Subjects With B-cell Malignancies

NCT04629729 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell
Chronic Lymphocytic Leukemia
Precursor B-Cell Acute Lymphoblastic Leukemia

Interventions

DRUG: FT819
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: IL-2
DRUG: Bendamustine

Sponsor

Fate Therapeutics